



^{52}gMn – a new PET tracer for preclinical in vivo neuroimaging

Napieczynska , Hanna; Severin, Gregory; Fonslet, Jesper; Pichler, Bernd J.; Calaminus , Carsten

Published in:
Proceedings - World Molecular Imaging Congress 2015

Publication date:
2015

[Link back to DTU Orbit](#)

Citation (APA):
Napieczynska , H., Severin, G., Fonslet, J., Pichler, B. J., & Calaminus , C. (2015). ^{52}gMn – a new PET tracer for preclinical in vivo neuroimaging. In *Proceedings - World Molecular Imaging Congress 2015*

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

TITLE: ^{52}gMn – a new PET tracer for preclinical *in vivo* neuroimaging

AUTHORS (FIRST NAME, LAST NAME): Hanna Napieczynska^{3, 1}, Gregory W. Severin², Jesper Fonslet², Bernd J. Pichler³, Carsten Calaminus³

ABSTRACT BODY:

Abstract Body: Introduction

Mn^{2+} is a Ca^{2+} analogue that can be taken up and transported by neurons in activity-dependent manner. It also crosses synapses and has been used for *in vivo* MRI of neural tracts. However, the element's toxicity limits its applications [1].

To overcome the problem we propose the radionuclide ^{52}gMn as a PET neuronal tract tracer. We evaluated two methods of tracer preparation and were able to visualize known neural pathways in a rat brain avoiding toxic effects.

Methods

^{52}gMn was produced by proton irradiation of $^{\text{nat}}\text{Cr}$ and isolated from excess Cr by either *i*) a combination of liquid-liquid extraction [2] and solid phase extraction on AG1x4 from 96:4 v/v EtOH: 12M HCl [3] or *ii*) three successive solid phase extractions against AG1x8 from 95:5 v/v EtOH:12M HCl with elution in 0,1M HCl and drying in between each extraction [4]. Both *i* and *ii* were prepared for injection in saline, buffered with 10mM sodium ascorbate (pH 6,5). Metallic impurities were quantified by ICPOES.

Rats were stereotactically injected with app. 170 kBq of ^{52}gMn (prepared by *i*) to the right ventral tegmental area (VTA) or dorsolateral striatum (DLS) (n=4). PET and MR images (T2W) were acquired 24h later. Another 4 rats were injected to the VTA with the decayed solution. All the animals underwent a rotameter test 4 weeks after the injection. Their brains were used for tyrosine hydroxylase (TH) staining.

With formulation *ii* 12 rats were injected to the VTA with 20 ± 5 kBq and scanned at 24h. They underwent the rotameter test 3 days, 2 weeks or 4 weeks (n=4) post-injection. The brains were used for TH- and H&E-staining.

Results

Formulation *ii* contained less impurities than *i* with a specific activity of 28 (*ii*) vs. 7,5 (*i*) GBq/ μmol and 0,8 (*ii*) vs. 4,5 (*i*) ng Cr/MBq. Moreover, *ii* omitted extractants: C_6H_6 , TOA, and NH_4OH .

Independently of the preparation method ^{52}gMn was transported along the mesolimbic and nigrostriatal pathways after injection to the VTA. Its highest amounts were found in the right ventral pallidum and in the nucleus accumbens. Following injection to the DLS the direct and indirect striatonigral pathways were visible in PET images. Autoradiograms confirmed the distribution of the tracer.

3 rats injected with formulation *i* rotated more to the ipsilateral than to the contralateral side in the rotameter test, indicating an imbalance of the motor control system. TH-staining revealed a dopaminergic lesion in those animals. However, there were no signs of toxicity after injections of the decayed solution, neither in the animals treated with *ii*. There was also no difference between the ipsi- and contralateral side of the H&E-stained brain tissues indicating no inflammation.

Conclusions

Our data show that ^{52}gMn traces neural pathways allowing visualization with PET. By using preparation method *ii* toxicity effects are avoided. In the future, imaging neural activity with ^{52}gMn may be possible.

References

[1] Inoue T, Majid T, Pautler RG, Rev Neurosci 2011, 22(6): 675-694.

- [2] Lahiri S, Nayak D, Korschinek G. Anal Chem 2006, 78:7517–21.
[3] Pietrzyk D, Fritz J. Atomic Energy Commision USA 1960; IS-337.
[4] Graves SA et al. Accepted as a poster at WMIC 2015, Control ID: 2230875.

TABLE TITLE: (No Tables)

(No Table Selected)

(No Image Selected)